Evidence map›Paper›PMID 37219486›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2023

Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity.

Junjie Chen, Douglas J Chapski, Jeremy Jong, Jerome Awada, Yijie Wang, Dennis J Slamon, Thomas M Vondriska, René R Sevag Packard

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Junjie ChenMolecular, Cellular, and Integrative Physiology Program, College of Letters and Science, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-8984-1986
Douglas J ChapskiDepartment of Anesthesiology & Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Jeremy JongDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Jerome AwadaDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Yijie WangDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Dennis J SlamonDivision of Hematology & Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Thomas M VondriskaMolecular, Cellular, and Integrative Physiology Program, College of Letters and Science, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
René R Sevag PackardMolecular, Cellular, and Integrative Physiology Program, College of Letters and Science, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-8520-5843
University of California, Los Angeles · USWest Los Angeles College · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Dynamics of Cardiac Nuclei in Heart DiseaseR01HL105699 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VONDRISKA, THOMAS M. · 2011 to 2025
$5.0M
Dissecting mechanisms of anthracycline-induced cardiotoxicityR56HL158569 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PACKARD, RENE R.S. · 2022 to 2022
$390k
Genomic structural dynamics in fibroblasts during heart failureF32HL160099 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHAPSKI, DOUGLAS JOSEPH · 2022 to 2023
$100k
Integrating 3-D Intravascular Sensors with Fractional Flow Reserve for Lipid-Rich PlaquesI01BX004558 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI PACKARD, RENE R.S. · 2020 to 2023
–
BLRD VA I01 BX004558NCATS NIH HHS UL1 TR001881NHLBI NIH HHS F32 HL160099NHLBI NIH HHS R01 HL105699NHLBI NIH HHS R56 HL158569
6 · The paper itself

Abstract

Anthracyclines such as doxorubicin (Dox) are effective chemotherapeutic agents; however, their use is hampered by subsequent cardiotoxicity risk. Our understanding of cardiomyocyte protective pathways activated following anthracycline-induced cardiotoxicity (AIC) remains incomplete. Insulin-like growth factor binding protein (IGFBP) 3 (Igfbp-3), the most abundant IGFBP family member in the circulation, is associated with effects on the metabolism, proliferation, and survival of various cells. Whereas Igfbp-3 is induced by Dox in the heart, its role in AIC is ill-defined. We investigated molecular mechanisms as well as systems-level transcriptomic consequences of manipulating Igfbp-3 in AIC using neonatal rat ventricular myocytes and human-induced pluripotent stem cell-derived cardiomyocytes. Our findings reveal that Dox induces the nuclear enrichment of Igfbp-3 in cardiomyocytes. Furthermore, Igfbp-3 reduces DNA damage, impedes topoisomerase IIβ expression (Top2β) which forms Top2β-Dox-DNA cleavage complex leading to DNA double-strand breaks (DSB), alleviates detyrosinated microtubule accumulation-a hallmark of increased cardiomyocyte stiffness and heart failure-and favorably affects contractility following Dox treatment. These results indicate that Igfbp-3 is induced by cardiomyocytes in an effort to mitigate AIC.

Indexed as

AnthracyclinesTranscriptomeAnimalsAntibiotics, AntineoplasticCardiotoxicityDNA AdductsDoxorubicinHumansMyocytes, CardiacRatsAnthracyclinesAntibiotics, AntineoplasticDNA AdductsDoxorubicindoxorubicin-DNAanthracyclinecardiomyocytescardioprotectioncardiotoxicitydoxorubicinIgfbp-3iPSC-CMNRVMtranscriptomics

Identifiers

PMID37219486
PMCPMC10286824
OpenAlexW4377564259

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.